Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

InflaRx N.v. IFRX

11 fiscal years on record · EUR · FY2025 reported · SEC filings only
€29,331
▼ 82.3% YoY
€-45.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

EUR 29,331.00
Revenue, FY2025 · full 11-year series below
Revenue €M Net income €M
FY2025 · Revenue 0.0 · Net income -45.6
-20M-40M
20152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE

No chart to show — the reason differs by year; see each year in the table below.

Three returns, three denominators.
Return on equityNot available: we don't have a clean profit figure for this period.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow €M
FY2021 · FCF -39.9
-15M-30M
201520202025
Net buybacks €M Dividends €M
FY2022 · Dividends 75.0 · Net buybacks ·
30M60M
2022

Total assetsEUR 55.2M
EquityEUR 7.2M
CashEUR 16.0M
Current ratio4.13×

Equity funds 13% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · EUR

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IFRX, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue €B0.00.00.0◌◌◌◌◌◌◌◌
Operating income €B◌◌−0.0−0.0−0.0◌◌◌◌◌◌
EBITDA €B◌◌−0.0−0.0−0.0◌◌◌◌◌◌
Income tax €B0.00.0◌◌0.00.00.00.00.00.00.0
Net income €B−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
Free cash flow €B◌◌◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted €−0.68−0.78−0.78−0.67−1.10−1.26◌◌◌◌◌
Dividend / sh $◌◌5.005.00◌◌◌◌◌◌◌
Payout %——◌◌———————
ROE % — not available in our data◌◌◌◌◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 5 failures in 43 reconciliationsAUDITED

Reconciled in 6 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 16 checks were skipped: revenue is not tagged before 2023. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency5 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image